ELN » Topics » Product Revenue from our EDT Business

This excerpt taken from the ELN 6-K filed Mar 31, 2008.
Product Revenue from our EDT Business
 
Manufacturing revenue and royalties are as follows:
 
                   
    2007
  2006
  % increase/
    $m   $m   (decrease)
 
TriCor
    62.5     52.1     20%
Skelaxin
    39.3     36.5     8%
Verelan
    28.5     36.3     (21)%
Focalin/Ritalin
    28.4     22.5     26%
Diltiazem
    18.7     19.5     (4)%
Other
    91.6     63.3     45%
                   
Total manufacturing revenue and royalties
    269.0     230.2     17%
                   
 
Manufacturing revenue and royalties from our EDT business comprise revenue earned from products we manufacture for third parties and royalties we earn principally on sales by third parties of products that incorporate our technologies.
 
Manufacturing revenue and royalties increased 17% to $269.0 million in 2007 from our 2006 sales level of $230.2 million. The increase primarily reflects continued growth across a number of products in our EDT portfolio and increased manufacturing activity.

40 Elan Corporation, plc 2007 Annual Report


Table of Contents

 
Financial Review
 
Except as noted above, no other single product accounted for more than 10% of our manufacturing revenue and royalties in either 2007 or 2006. In 2007, 47% of these revenues consisted of royalties received on products that we do not manufacture, compared to 44% in 2006.
 
Potential generic competitors have challenged the existing patent protection for several of the products from which we earn manufacturing revenue and royalties. We and our clients defend our intellectual property rights vigorously. However, if these challenges are successful, our manufacturing revenue and royalties will be materially and adversely affected.
 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki